Sign up Australia
Proactive Investors - Run By Investors For Investors

Paradigm Biopharmaceuticals meets primary endpoint in clinical trial

Paradigm aims to repurpose pentosan polysulfate sodium (PPS), an FDA-approved drug.
folder with title reading clinical trial
Paradigm is also conducting two other phase 2 clinical trials

Paradigm Biopharmaceuticals (ASX:PAR) has received results from its phase 2a clinical trial in bone marrow lesions (bone bruising) as a result of an anterior cruciate ligament (ACL) injury.

Importantly, the primary endpoint of safety and tolerability was met.

Paradigm was also successful in meeting its secondary endpoint, demonstrating a statistically significant reduction in bone marrow lesion (BML) volume as measured by MRI.

The top line results come from the analysis of safety data on 11 people who participated in the phase 2a open label trial to evaluate the drug, pentosan polysulfate (PPS).

The trial success confirms the company’s hypothesis that PPS could be a new treatment for acute joint injuries.

Secondary endpoint

Overall 6 of 9 (66.6%) participants showed reduction in BML and 8 of 9 (88.8%) had reduction in effusion-synovitis volume.

These results indicate that PPS has potential to significantly improve recovery from acute ACL injury, with significant improvement in both bone marrow lesion volumes and effusion volumes, function improvement and improved long-term outcomes for patients.

Paradigm’s patent to treat BMLs with PPS is already granted in the U.S, Japan and Australia.

The multi-billion dollar post-traumatic osteoarthritis (PTOA) market is very large with unmet medical needs.

Paul Rennie, CEO, commented

“The statistically significant reduction of both bone marrow lesion volume and effusion-synovitis volume is very encouraging data.

“Paradigm is delighted that the open labelled clinical trial (with blinded analysis of MRI’s before and after PPS treatment) successfully achieved its primary and secondary endpoints.

“We are also delighted to show for the first time both BML volume and effusion-synovitis volume was significantly reduced within a 2-month period postacute injury.

“We are hopeful the drug PPS could become standard of care, post-surgical reconstruction, with the potential to reduce the risk of a person developing PTOA”.

Other trials in process

In addition to the ACL clinical trial, Paradigm is also conducting two phase 2 clinical trials in degenerative osteoarthritis and viral induced arthritis.

The degenerative osteoarthritis is a phase 2b randomised, double-blind, placebo-controlled clinical trial with 100 patients.

The viral induced arthritis is a phase 2a randomised, double-blind, placebo-controlled clinical trial with 24 patients.

Paradigm expects to update the market on the recruitment status of these two trials in the coming weeks.

READ NOW: Paradigm Biopharmaceuticals funded into 2019 through placement

View full PAR profile View Profile

Paradigm Biopharmaceuticals Ltd Timeline

Related Articles

Regeneus: Access latest PPT from Proactive's CEO Sessions
June 19 2017
John Martin discussed regenerative medicine with investors.
Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
boy leaning against chain link fence
September 14 2017
We take a look back at the progress made by Summit in the five years since we first spoke to chief executive Glyn Edwards

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use